Mirum Pharmaceuticals, Inc.
MIRM
Rank in Stocks
#3354
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Share Price
$80.17
Last synced: 2026-10-16
Market Cap
$5.21B
Change (1 day)
-2.69%
Change (1 year)
9.03%
Country
US
Trade Mirum Pharmaceuticals, Inc. (MIRM)
Category
Healthcare
EPS for Mirum Pharmaceuticals, Inc. (MIRM)
EPS as of June 2026 TTM: $-14.56
According to Mirum Pharmaceuticals, Inc. latest financial reports and stock price the company's current EPS (TTM) is $-14.56. At the end of 2023 the company had a EPS of $-4.00 a decrease compared to its 2022 EPS that were of $-4.01.
EPS history for Mirum Pharmaceuticals, Inc. from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-14.56 | 687.03% |
| 2024 | $-1.85 | -53.75% |
| 2023 | $-4.00 | -0.25% |
| 2022 | $-4.01 | 44.77% |
| 2021 | $-2.77 | -32.27% |
| 2020 | $-4.09 | 78.60% |
| 2019 | $-2.29 | 205.33% |
| 2018 | $-0.75 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $17.32 | -218.96% |
US
|
|
| $-7.98 | -45.19% |
US
|
|
| $-5.29 | -63.67% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -290.52% |
NL
|
